09 March 2021
Australia’s Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency with or without anemia in adults
Shield Therapeutics plc, notes that Australia’s Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anemia in adults.
Feraccru® is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia.
The Therapeutic Goods Administration (TGA) is Australia’s regulatory authority for medicinal products (“therapeutic goods”).